Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119520 | 0.98 | SLC6A2 (0.46) | SLC6A2SLC6A4GBA1HTR2ATAAR1 | |
| SCHEMBL23574239 | 0.88 | SLC6A2 (0.44) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL6770189 | 0.88 | KMT2A (0.46) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL24622493 | 0.87 | SLC6A2 (0.41) | SLC6A2SLC6A4GBA1HTR2ATAAR1 | |
| SCHEMBL19110509 | 0.86 | LTA4H (0.46) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL2090678 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4GBA1HTR2ATAAR1 | |
| SCHEMBL578602 | 0.83 | GBA1 (0.66) | SLC6A2SLC6A4GBA1CHRM2CCR5 | |
| SCHEMBL578726 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A4CCR3ATMCHRM2 | |
| SCHEMBL31352696 | 0.78 | GBA1 (0.43) | SLC6A2SLC6A4GBA1CCR3ATM | |
| SCHEMBL16572190 | 0.77 | NPC1 (0.39) | SLC6A2SLC6A4HTR2ATAAR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | SLC6A2 4571/4885SLC6A4 2631/4885GBA1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.